Lupin Limited has officially finalized the acquisition of VISUfarma B.V., a Netherlands-based company. Following the fulfillment of all customary closing conditions, the acquisition became effective on April 1, 2026. Through this strategic transaction, VISUfarma and its wholly owned subsidiaries have been integrated into Lupin’s subsidiary, Nanomi B.V., marking a significant expansion of the company’s international portfolio.
Strategic Business Expansion
Lupin has successfully concluded its acquisition of the entire share capital of VISUfarma B.V., based in the Netherlands. This move, which was previously announced in late 2025 and early 2026, is now fully effective as of April 1, 2026. The completion of this deal follows the satisfaction of all standard closing requirements, solidifying the integration process.
Integration and Future Operations
The acquisition was facilitated through Nanomi B.V., a wholly owned subsidiary of Lupin. With the deal finalized, both VISUfarma B.V. and its own network of wholly owned subsidiaries now operate as wholly owned units under the Nanomi umbrella. This structural integration is expected to support Lupin’s ongoing growth initiatives and strengthen its presence within the pharmaceutical landscape.
Source: BSE
